A rapidly increasing number of studies are being published providing significant results by the use of tissue microarrays (TMAs), ie, paraffin blocks composed of multiple specimens. The numerous advantages of this technology are obvious and have thus stimulated many constructors to evolve and improve different technical approaches. With TMAs, multiple specimens can be simultaneously investigated with different in situ techniques under identical laboratory conditions, resulting in a dramatic time and cost reduction compared with conventional pathologic studies. Furthermore, this technology is less exhausting for the finite original donor material, allowing for a significantly increased number of assays per each case. Against the background of decoding the human genome and the widespread application of high-density cDNA microarrays, the next challenge will be to apply the genome discoveries to the clinical setting. For pathologists, TMAs represent an ideal adjunct and can be very useful for the rapid and high-throughput discovery and validation of countless candidate biomarkers, assessing their prognostic and predictive value and identifying further therapy targets. This article provides a review of different TMA technologies and addresses the technical aspects of their construction and their validity in different applications through data from the literature along with the authors' own experiences.
TISSUE MICROARRAY HISTORY
In 1965, Lilie 1 first described the "special blocking and trimming procedure for cross sections of multiple small tubular structures" in his Histopathologic Technic and Practical Histochemistry. Since then, an evolutionary process has begun to refine and optimize the technical application of tissue microarrays (TMAs). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Early approaches were limited to the prospective embedding of relatively large specimens, and assembling of blocks was hampered by the need to embed manually high numbers of samples into 1 paraffin block without further supplies. 1, 3, 5 It was Hector Battifora 4,9 who overcame several of those obstacles by introducing his "multitumor sausage block" and, a few years later, his "checkerboard tissue block." Although improving the technical state of the art at that time, the construction of multitumor tissue blocks was still time consuming and required deparaffinization and re-embedding of the desired tissue samples. Furthermore, only larger tissue specimens were appropriate for cutting tissue rods, and special equipment such as a multiblade knife, a tissue embedding mold, and a cubel cassette was needed. 4, 8, 9, 11 Using a cannula to directly punch out tissue cores from archival paraffin blocks was described first by Wan et al 6 in 1987. This technical improvement abolished the laborious rod cutting and re-embedding of the tissues designated for a TMA and introduced a new generation of TMA.
TECHNICAL ASPECTS OF MODERN TISSUE MICROARRAYS

Different Construction Systems
Currently, from a technical point of view, 2 different TMA systems are available: the Beecher system (Beecher Instruments, Sun Prairie, WI) and the MaxArray System (Zymed Laboratories Inc, South San Francisco, CA). The former is a semiautomatic or, recently, fully automatic machine. Based on this technical approach, numerous commercial suppliers (Table 1) offer ready-to-use TMA slides with embedded cell lines, animal or human tissues, or a service for the construction of customer TMAs. A different technique for TMA construction is used for the commercial service called the MaxArray System. Both systems are based on punching out tissue cores from archival donor paraffin blocks. This approach allows selecting a precise tissue area of interest (tumor, invasive, in situ, normal tissue, tumor-normal tissue interface) by reviewing a corresponding hematoxylin and eosin slide of the donor block and marking the desired area (Figs. 1, 2) . Relatively small donor specimens can be used in a less exhausting way for the finite original donor material. Therefore, the differences (Table 2) between the 2 systems are attributed to different construction procedures of the TMA after punching out the tissue cores.
With the Beecher system, a machine is purchased with a cannula and the facility to move a preformed recipient paraffin block precisely on an x-axis and y-axis. With the cannula, a tissue core is punched out from the donor block and moved semiautomatically to the correct position over a preformed hole in the recipient block. At this position, the tissue core is pressed out of the cannula into the preformed hole by a steel pin. Then the recipient block is moved precisely with a micrometer screw into the correct position for the next tissue core. This process is continued for all tissue cores until the desired block is finished. Depending on the diameter of the cannula, different numbers of specimens (as many as 1000 or more) can be brought into 1 TMA. However, one disadvantage of very thin tissue cores and machine-based construction is that storing of punched out tissue cores is not possible. If a specimen were brought later into another TMA, the donor block would have to be recruited again from the archive. Additionally, for TMAs constructed with the Beecher system, a special paraffin sectioning aid system (adhesive-coated slides), adhesive tape, and an ultraviolet lamp are recommended to support the cohesion of the cut tissue cores on the glass slide. 19, 20 However, the adhesion tape might cause impaired result with some specific in situ assays. This might challenge the use of conventional charged slides with similar results as reported recently. 21 As described by Bubendorf et al 22 from the group working first with this machine, the whole procedure demands a significant training period, including a few 1000 punches. Furthermore, an enduring personality and good eyes are important prerequisites for operators of the current semiautomatic machine. No data are available in the literature on whether these obstacles are eliminated by the fully automatic next generation of punching machines.
In the MaxArray System, with an easy-to-use hand device provided by the supplying company, the researcher punches out the tissue cores. The tissue cores are sent to the company, where the TMA is constructed by melting all tissue cores together into a new, homogeneous paraffin block. Before this melting process, the tissue cores are arranged in a checkerboard manner that is predetermined by the researcher and allows for the definite identification of each tissue core in the final TMA. Thus, the entire technical portion of the array construction is performed by the company, generally with a turnaround time of 2 to 4 weeks. With this system, the obtained tissue cores can easily be stored and sent around the world (Figs. 3, 4 ). An advantage of this is that in 1 session, numerous tissue cores can be obtained and stored in microtubes for further arrays or even for isolation of RNA or DNA from the same area as investigated in the TMA. The main difference between the 2 systems is that with the Beecher system, the tissue cores are tightly placed in soft paraffin in the recipient block, whereas with the MaxArray System, the tissue cores are entirely melted together with the surrounding conventional paraffin of the recipient block.
In addition to TMA in paraffin, methods have been published recently for the construction of tissue arrays composed of frozen tissue specimens. 17, 23 We have constructed frozen TMAs covering as many as 60 tissue cores, opening new avenues for widespread in situ analysis of RNA, DNA, and proteins (Fig. 5 ).
Tissue Loss
Loss of tissues is a well known and long-term problem with conventional stains. Influencing factors are tissue fixation and processing and the tissue type itself (eg, fat). Especially for techniques using heat-induced antigen retrieval, the floating of tissue from the surface of glass slides may become a problem. Using TMAs, an increased rate of tissue loss by floating may be expected because of the small size of the tissue cores.
For the more recent TMA systems in the literature, varying percentages of tissue loss are described, depending on the tissue in the TMA and the applied construction system. Since the advent of the Beecher machine, 13 numerous studies have been performed using TMAs constructed in that way, and some give detailed data concerning tissue loss caused by floating, varying between 3% and 25%. 16, 19, 20 However, a tissue spot on a TMA slide can be noninformative not only because of floating during the staining procedure but also for other reasons. For example, a tissue spot might not be present on the glass slide because no more slices can be cut from the TMA block, informative tissue is not represented in the tissue core ("mispunching"), or a tissue spot on the edge of the glass slide is not sufficiently stained. Putting together all options that result in noninformative tissue spots (NITSs), accordingly higher percentages of cases were described that were not available for evaluation (15%-37%) when TMAs were constructed with the Beecher system. 16, 19, 20 With the manual MaxArray System, applied by our group in a large nationwide quality assurance trial with 172 participating laboratories, lower rates (0.6%-1%, depending on the marker used) of tissue loss by floating from the slide surface were observed. These rates were observed in spite of the fact that within the trial, more than 100 serial sections from each TMA were performed, and on these, the 172 participants performed 688 immunohistochemical stains with a diversity of pretreatment techniques. From the more than 20,000 stained tissue spots (172 participants × 4 antibodies × 30 tissue cores per TMA), less than 1% were not possible to evaluate because of floating. Considering all reasons contributing to NITSs, more than 92% of the tissue cores could still be evaluated within this multicenter trial. [24] [25] [26] Although detailed data are missing on a direct comparison of both systems, the data so far available hint to the fact that not only is floating of tissue spots more frequently observed with the Beecher system, but also the rate of NITSs is considerably higher. As a possible reason for the latter effect, one might assume that the smaller diameter of the needle results in a higher rate of mispunching. 21 The higher rate of floating with the Beecher system may be explained by the technical differences in the construction of the TMA: whereas the construction of MaxArray TMA results in a homogenous, fully melted paraffin block, the Beecher system is constructed with cold paraffin, ie, the paraffin in the tissue core is not completely connected to the surrounding paraffin of the recipient block.
Evaluation of Staining Results
Early systems without a symmetric checkerboard arrangement require a person more experienced in morphology for orientation and evaluation spending a greater time, sometimes not reaching a definite identification of individual tissue rods. Modern TMA slides with an exact x-y positioning of each tissue core are straightforward to handle, and it is easy to get one's bearings because of a tissue core that is in an exposed localized position and clearly identifiable. However, the larger the array and the smaller the cores, the more difficult the orientation. Nevertheless, stains can be read out quickly and continuously by 1 person and fed simultaneously by another into a computer database with the patient's follow-up data. This process allows for a rapid transition of staining results into clinical outcome by standard software packages (eg, SPSS). Furthermore, TMA format is particularly well suited for different image analysis approaches, providing for an automatic read-out. 27, 28 The TMA technique solves a major obstacle for automated slide interpretation-the selection of a representative area for analysis. This has already been achieved during the selection of the regions to be punched out. 22 
Data Management
It is predicable that TMAs are generating growing amounts of data demanding adequate data management. A meaningful database must record the relevant patient's data, allowing for a reliable connection to clinical follow-up databases, and also all relevant pathologic data such as tissue type, tumor or disease entity, grading and staging to each case, and-most importantly-all data for each tissue core in every TMA. The location information of the tissue core is decisive to identify each patient, and all staining results must be recorded accordingly. Also, further optional information, such as the available number of additional tissue cores or digital images, should be stored in a relational database. This is, on the one hand, the only way to handle the rapidly increasing amount of generated data, and on the other hand, the backbone of a rapid and reliable transition of staining results to clinical outcome. There are existing Web-based database structures to handle clinical and pathology data for each patient in a TMA, easily facilitating intrainstitutional and interinstitutional collaborations. 29, 30 Data management is crucial and should be well established before any substantial application of TMAs is begun.
Tissue Heterogeneity: A Frequently Asked Question
Another concern about TMAs is to what extent tissue heterogeneity is affecting the validity and reproducibility of results obtained by this technique. Concerning tissue heterogeneity, one must differentiate between diagnostic pathology, in which heterogeneity can be a decisive element of the diagnosis, and research pathology. Numerous recent studies have investigated in detail the question of tissue heterogeneity using TMAs for research approaches, addressing pathogenetic and pathoepidemiologic questions. 14, 16, 19, 22, 23, 27, 28, [31] [32] [33] Until now, only 1 study has performed a pathomorphologic grading on TMA slides investigating urinary bladder carcinomas. 34 Summarizing the results of most of these studies, it can be concluded that the findings that have been revealed from large tissue samples can be fully reproduced in TMA. Nocito et al 34 examined the Ki-67 labeling index and re-evaluated the histologic grade in TMAs from 2317 urinary bladder carcinomas. All associations of the histologic grade and the Ki-67 labeling index with prognosis that were determined from large tissue samples could be fully reproduced on the TMAs. Similar results were published for breast cancer. Torhorst et al 33 showed with a TMA composed of 553 cases of breast cancer that the prognostic value of estrogen receptor, progesterone receptor, and p53 can be entirely reproduced. Also with prostate cancer, which is well known for its heterogeneity, TMAs proved to be a reliable tool for evaluating the prognostic value of biomarkers. 28 Other studies compared results from TMAs with results in the literature from classic pathologic studies on large tissue samples. This comparison was performed in the first description of modern TMAs by Kononen et al 13 in 1998. They found the same frequencies of HER-2, c-myc, cycline D1, and 17q23 amplifications in breast cancers as were expected from the literature. Schraml et al 19 investigated different tumor entities in a TMA by fluorescent in situ hybridization (FISH) for the amplification of CCND1, c-myc, and HER-2 and were able to reproduce the published data. We took a similar approach when establishing TMAs in our laboratory. We first stained well characterized standard prognostic biomarkers on TMAs for each tumor entity and then correlated the results to the literature before starting with new biomarkers of unknown prognostic value. 35 A third group of studies directly compared results from TMAs with those from large tissue samples. Hoos et al 23 analyzed 59 fibroblastic tumors for their expression of Ki-67, p53, and retinoblastoma protein and compared the data of large tissue samples to results from 1 TMA. For Ki-67, the concordance between TMA and large tissue samples was 96%; for p53, it was 98%; and for retinoblastoma protein, it was 91%. Camp et al 27 compared TMAs with 2 to 10 tissue cores (0.6 mm in diameter) per case with conventional large tissue samples of breast cancer and found that for ER, PR, and HER-2 stains, 2 tissue cores were enough, with a concordance of more than 95%. Similar results for ER and PR in breast cancer were presented by Gillett et al 14 with a self-made TMA system. However, it may be presumed that TMA studies that include only 1 tissue core per case can provide meaningful results, especially if the number of included cases is large enough, suggesting that the effects of intratumor heterogeneity are averaged out in large-scale analysis. 32, 34 Substantial data are lacking on whether the diameter of the needle used for punching out the tissue cores has any influence on the results obtained by TMAs. It can be assumed that increasing the needle size may only slightly influence tumor heterogeneity. Taking 2 or more tissue cores from different tumor areas could be a more promising approach to retort tumor heterogeneity. This approach may otherwise lead to problems when evaluating the staining results. If 1 of 2 or 3 tissue cores of a case is positive, is the whole case positive or not? These deliberations result in a dilemma similar to that seen with conventional slides, for which 1 observer may read the staining in the upper left corner, whereas a second observer may expect a different staining result and evaluates the (diverging) staining on the lower right tissue area. This effect obviously contributes to different immunohistochemical results published for many markers and carcinomas. Reading only 1 tissue spot of a TMA may even improve the interobserver agreement, but neither TMAs nor conventional slides (which in the end also represent a minor portion of the whole tumor) are able to overcome the problem of tissue heterogeneity as is seen in some markers. Even more striking is the fact that systematic data concerning this question are completely lacking.
TISSUE MICROARRAY APPLICATIONS Target Profiling in Pathology
Principally all tissues, techniques, and protocols for working on large tissue samples (paraffin or frozen) are also suitable for TMAs. Depending on the aim of the desired study, the layout of a TMA should be planned prospectively. Describing the expression pattern of new biomarkers or RNA or DNA probes, a TMA should include almost a complete spectrum of normal tissues and of common tumor entities. 4 Also suitable for similar purposes are cell lines, which can easily be fixed and embedded in paraffin and then brought into a TMA. For example, in animal studies, all organs of 1 animal or the organs of interest of all animals of 1 cohort can be brought into 1 TMA and simultaneously investigated. TMAs for pathoepidemiologic survival studies are composed of tissue cores in a clearly identifiable position, enabling a definite assignment to a patient's individual follow-up data. Otherwise, markers involved in tumor progression or pathogenetic pathways can be investigated by different TMA patterns. For example, a TMA is composed of cores from a tumor from its center, its tumor-normal tissue interface, and its adjacent normal tissue, or from invasive parts of a tumor and in situ parts of the same tumor, or even different tumors of the same entity at different stages and gradings.
The power of TMAs become obvious when they are simultaneously used with different in situ techniques, eg, immunohistochemistry and FISH, or in combination with other techniques, eg, cDNA arrays or laser microdissection. [36] [37] [38] [39] [40] Such combinations enable a much quicker identification of genes and gene products involved in the pathogenesis and progression of human diseases. The prognostic and predictive values of candidate genes or biomarkers revealed in this way can be reliably proven within days.
Quality Assurance in Pathology
Because the role of immunohistochemistry has changed from an ancillary diagnostic technique to a method that can lead directly to a specific treatment approach (eg, HER-2 in breast cancer), quality assurance is crucial in diagnostic pathology. 41, 42 TMAs are a well suited and cost-effective tool for quality control and standardization in numerous approaches of diagnostic and research immunohistochemistry.
With single-center research studies, the application of TMA can already improve staining quality because positive and negative controls can be easily included in the TMA. All cases are stained simultaneously under identical laboratory conditions, circumventing day to day variations. Also, the evaluation of the different biomarkers within a study will be more standardized because nearly identical tissue areas of a case are evaluated for each biomarker. All these advantages of the TMA technique will improve the quality and reduce the bias of single-center studies. Additionally, the influence of tissue fixation and processing on new biomarkers can be evaluated precisely with respectively designed TMAs composed of variable fixed and processed tissue specimens. 25, 26, 43 Furthermore, small-scale TMAs composed of well characterized positive and negative controls as controlled, fixed archival cases-or, even better, as cell lines-can serve as controls in the daily routine. 12, 44 Such mini-TMAs, composed of fewer than 10 tissue cores, can be easily mounted on a glass slide together with the specimen of interest (ie, on slide control array). With this approach, the control is stained identically with the specimen of interest without any additional work or consumption of reagents (Fig. 6) . Finally, the control is archived together with the specimen, allowing later years to demonstrate the quality and reliability of an individual stain.
Interinstitutional quality comparison can be a firm part of multicenter research studies when using TMAs. For example, participating laboratories can supply cases, and slides from the consecutively constructed TMA are sent back to all participants and decentrally stained and evaluated, with re-review afterward by all participants. 22 Studies the other way around are also possible, so that 1 center is sending TMA slides to participating centers. Revealed results will provide a high statistical impact not only by the high-throughput TMA but also by the decreased bias and increased quality assurance.
For extrainstitutional quality assessment, TMAs are very useful tools to perform large multicenter trials in a cost-effective way for quality evaluation in diagnostic immunohistochemistry. [24] [25] [26] TMAs enable a high number of participants to receive a meaningful number of nearly identical test cases on only 1 slide, with several advantages. Day to day variations are excluded in the participating laboratories; all participants stain and evaluate nearly identical tissue areas of the same cases; heterogeneity is widely excluded; and efforts, time, and cost are low in relation to a high number of participants. TMA-based multicenter trials are suitable not only to evaluate the status quo of the participants but also to survey the quality development on a regular basis. This advantage makes them a proper tool of quality assurance not only in immunohistochemistry but also in all other diagnostically applied in situ techniques (eg, FISH).
CONCLUSIONS AND PROSPECTS FOR TISSUE MICROARRAY
In recent years, TMAs have showed a remarkable acceleration of their technical development and spreading application in research studies. This expansion is already reflected by the fact that nearly half of all abstracts from the 91st Annual Meeting of the United States and Canadian Academy of Pathology applying in situ techniques to archival paraffin-embedded tissues used TMAs. 45 The most likely explanation for this recent acceleration is that since the advent of Battifora's "sausage block," systems have been developed that are much easier to handle and available for everyone. It can be anticipated that pathologists will be unable to avoid using TMAs for the rapid and cost-effective screening of large tumor series, speeding the transition of new biomarkers to clinical followup data.
The most obvious concerns about TMAs regarding the influence of tissue heterogeneity could be eliminated by numerous, thorough studies comparing TMAs and conventional large tissue slides. 14, 20, 27, 28, 32, 33 Technical aspects concerning construction, tissue loss, and handling of the TMA while cutting depend on the TMA system used. An upcoming question may be which TMA system is the best. The answer depends on the aims of the study, the number of cases to be incorporated, the availability of staff and money in the institution, and the attitude of the user. Without doubt, the Beecher system allows the construction of TMAs composed by far of the highest number of tissue cores. However, with this technique, relatively high numbers for tissue loss are given in the literature. 16, 19 If a group can anticipate that TMAs will be applied in a large-scale, routine fashion, the initial costs and staff costs for the Beecher system will be amortized. If a group or an institution is planing to use TMAs for definite or limited projects and no time and staff for the establishment of a new technique are available, commercial full services providing individual customer TMAs seem to be the more flexible approach.
In the future, the retrospective and the prospective construction of TMAs from every incoming tumor or desired tissue specimen in pathologic institutions can be a powerful approach in the transition of the rapidly increasing number of new biomarkers into clinical settings. For this, a decisive prerequisite will be the careful and comprehensive collection and documentation of corresponding clinical follow-up data. The next step should be pathoepidemiologic studies identifying the biomarkers that have significant impact on tumor biology. Following that, a further detailed molecular analysis of specific pathways in tumor progression would be more promising.
Independently from the applied TMA system, with or without automatic image analysis, huge amounts of data will be produced. As with the rapidly increasing cDNA array data, the decisive challenge with TMAs will be the data management. 29, [46] [47] [48] [49] Nevertheless, it appears that a new era is about to dawn, when the first real patient benefit can be attributed to the efforts of the Human Genome Project. 
